Different Medications for Preventing 131I-induced Salivary Gland Damage in Thyroid Cancer Patients：a Network Meta-analysis

doi:10.12114/j.issn.1007-9572.2021.02.017

Abstract

Abstract: Background　Although 131I adjunctive therapy can significantly improve the survival rate of patients with thyroid cancer，its induced salivary gland damage seriously affects the quality of life. Currently，there are a variety of drugs for the prevention and treatment of 131I-induced salivary gland damage，but it needs to conduct a network Meta-analysis to fill the gap of comparison of these medications. Objective　To perform a network Meta-analysis of different medications for preventing 131I-induced salivary gland damage in thyroid cancer patients. Methods　Randomized controlled trials（RCTs） or non-RCTs about different medications for preventing 131I-induced salivary gland damage in thyroid cancer patients were searched in databases of Cochrane Central Register of Controlled Trials，Web of Science，PubMed，and EMBase，VIP，CNKI，Wanfang Data and SinoMed from inception to January 2021. Literature screening and data extraction were performed by two researchers，separately. The literature quality was evaluated using the risk of bias assessment tool in the Cochrane Handbook for Systematic Reviews of Interventions（Version 5.1.0） and MINORS. Consistency test，publication bias analysis and graph drawing were carried out using Stata 16.0. OpenBUGS 3.2.3 was used for network Meta-analysis. Results　A total of 11 articles were included，involving 7 intervention schemes：amifostine，vitamin C，amifostine with vitamin C，citric acid，vitamin E，selenium and propylthiouracil. Network Meta-analysis revealed that in terms of preventing 131I-induced loss of salivary excretion fraction in the parotid gland，amifostine with vitamin C was superior to citric acid and propylthiouracil，so was amifostine（P<0.05）. Amifostine was also superior to the regular treatment（P<0.05）. The SUCRA score for the schemes in preventing 131I-induced loss of salivary excretion fraction in the parotid gland ranked from highest to lowest was：amifostine with vitamin C> amifostine > vitamin C>regular treatment > vitamin E> selenium >citric acid > propylthiouracil. In terms of preventing 131I-induced loss of salivary excretion fraction in the submandibular gland，propylthiouracil was inferior to vitamin E，amphostine with vitamin C，amphostine and regular treatment（P<0.05）. The SUCRA score for the schemes in preventing 131I-induced loss of salivary excretion fraction in the submandibular gland ranked from highest to lowest was：vitamin E>amphostine with vitamin C> amphostine>selenium> vitamin C> citric acid> regular treatment > propylthiouracil. The funnel plot of comparing different medications for preventing 131I-induced loss of salivary excretion fraction in the parotid gland or submandibular gland was obviously symmetrical. Conclusion　Amphostine with vitamin C may be the best intervention for preventing 131I-induced loss of salivary excretion fraction in the parotid gland. And vitamin E may be the best scheme for preventing 131I-induced loss of salivary excretion fraction in the submandibular gland，followed by amphostine with vitamin C. Due to limitations of this study，these results should be taken with caution，which still need to be verified by more large-sample，high-quality clinical studies.

Key words: Thyroid neoplasms, Salivary glands, 131I irradiation, Protective effect, Network Meta-analysis

摘要： 背景　131I辅助治疗甲状腺癌可显著提高患者生存率，但由此引起的唾液腺损伤严重影响患者生存质量。目前对于防治唾液腺损伤的药物有多种，但缺乏药物疗效之间的比较，因此进行网状Meta分析至关重要。目的　采用网状Meta分析方法评价不同药物干预方案对131I辅助治疗甲状腺癌患者唾液腺功能的保护作用。方法　计算机检索Cochrane Central Register of Controlled Trials、Web of Science、PubMed、EMBase、维普网、中国知网、万方数据知识服务平台、中国生物医学文献服务系统建库至2021年1月发表的不同药物干预方案对131I辅助治疗甲状腺癌患者唾液腺功能保护作用的随机对照试验或非随机对照试验。由两名研究者筛选文献，提取研究资料；使用Cochrane Handbook 5.10偏倚风险评估工具和MINORS评价文献质量，Stata 16.0软件进行一致性检验、发表偏倚分析和图形绘制，OpenBUGS 3.2.3软件进行网状Meta分析。结果　共纳入11篇文献，涉及7种药物干预方案，分别为氨磷汀、维生素C、氨磷汀+维生素C、柠檬酸、维生素E、硒、丙硫氧嘧啶。网状Meta分析结果显示，对腮腺排泌分数（EF）的防护作用氨磷汀+维生素C、氨磷汀高于柠檬酸和丙硫氧嘧啶，氨磷汀高于常规治疗（P<0.05）；累积排序概率图下面积（SUCRA）排序：氨磷汀+维生素C>氨磷汀>维生素C>常规治疗>维生素E>硒>柠檬酸>丙硫氧嘧啶。对颌下腺EF的防护作用维生素E、氨磷汀+维生素C、氨磷汀、常规治疗高于丙硫氧嘧啶（P<0.05）；SUCRA排序：维生素E>氨磷汀+维生素C>氨磷汀>硒>维生素C>柠檬酸>常规治疗>丙硫氧嘧啶。腮腺EF和颌下腺EF的漏斗图对称性良好。结论　氨磷汀+维生素C可能是防护131I辅助治疗甲状腺癌患者腮腺排泌功能的最佳干预方案，维生素E可能是防护131I辅助治疗甲状腺癌患者颌下腺排泌功能的最佳干预方案，氨磷汀+维生素C次之；但因网状Meta分析的局限性，仍需谨慎对待此结果，建议进行更多高质量、大样本的临床研究进一步验证。

关键词: 甲状腺肿瘤, 唾液腺, 131I治疗, 保护作用, 网状Meta分析

MA Dan,YIN Xinbo,LIU Jiahui, et al. Different Medications for Preventing 131I-induced Salivary Gland Damage in Thyroid Cancer Patients：a Network Meta-analysis　[J]. Chinese General Practice, 2021, 24(30): 3828-3836. DOI: 10.12114/j.issn.1007-9572.2021.02.017.
马丹,尹新博,刘佳惠等. 不同药物干预方案对131I辅助治疗甲状腺癌患者唾液腺功能保护作用的网状Meta分析[J]. 中国全科医学, 2021, 24(30): 3828-3836. DOI: 10.12114/j.issn.1007-9572.2021.02.017.

References

［1］KIM J，GOSNELL J E，ROMAN S A.Geographic influences in the global rise of thyroid cancer［J］. Nat Rev Endocrinol，2020，16（1）：17-29. DOI：10.1038/s41574-019-0263-x.
［2］LEE K，ANASTASOPOULOU C，CHANDRAN C，et al. Thyroid cancer//StatPearls［Internet］［M/OL］. Treasure Island（FL）：StatPearls Publishing，2021.
［3］张洁，闫贻忠，王丹，等. 2005—2014年中国肿瘤登记地区甲状腺癌发病的时间趋势分析［J］. 现代预防医学，2020，47（4）：577-582，591.
ZHANG J，YAN Y Z，WANG D，et al. Time trend analysis of thyroid cancer incidence in tumor registration areas of China from 2005 to 2014［J］. Mod Prev Med，2020，47（4）：577-582，591.
［4］马晶昱，周衍，林永添，等. 2016年福建省肿瘤登记地区恶性肿瘤发病和死亡分析［J］. 中国肿瘤，2021，30（4）：241-249.
MA J Y，ZHOU Y，LIN Y T，et al. Analysis of incidence and mortality in Fujian cancer registries，2016［J］. China Cancer，2021，30（4）：241-249.
［5］ESTORCH M，MITJAVILA M，MUROS M A，et al. Radioiodine treatment of differentiated thyroid cancer related to guidelines and scientific literature［J］. Rev Esp Med Nucl Imagen Mol（Engl Ed），2019，38（3）：195-203. DOI：10.1016/j.remn.2018.12.008.
［6］中国临床肿瘤学会指南工作委员会甲状腺癌专家委员会.中国临床肿瘤学会（CSCO）持续/复发及转移性分化型甲状腺癌诊疗指南-2019［J］. 肿瘤预防与治疗，2019，32（12）：1051-1079. DOI：10.3969/j.issn.1674-0904.2019.12.003.
Expert Panel on Thyroid Cancer，Guidelines Working Committee of Chinese Society of Clinical Oncology.Guidelines of Chinese Society of Clinical Oncology（CSCO）：persistent/recurrent and metastatic differentiated thyroid cancer-2019［J］. J Cancer Control Treat，2019，32（12）：1051-1079. DOI：10.3969/j.issn.1674-0904.2019.12.003.
［7］JENTZEN W，SCHNEIDER E，FREUDENBERG L，et al. Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer［J］. Nucl Med Commun，2006，27（8）：669-676. DOI：10.1097/00006231-200608000-00009.
［8］ZERDOUD S，GIRAUDET A L，LEBOULLEUX S，et al. Radioactive iodine therapy，molecular imaging and serum biomarkers for differentiated thyroid cancer：2017 guidelines of the French Societies of Nuclear Medicine，Endocrinology，Pathology，Biology，Endocrine Surgery and Head and Neck Surgery［J］. Ann Endocrinol（Paris），2017，78（3）：162-175. DOI：10.1016/j.ando.2017.04.023.
［9］CIARALLO A，RIVERA J.Radioactive iodine therapy in differentiated thyroid cancer：2020 update［J］. AJR Am J Roentgenol，2020，215（2）：285-291. DOI：10.2214/AJR.19.22626.
［10］BOHUSLAVIZKI K H，KLUTMANN S，BRENNER W，et al. Salivary gland protection by amifostine in high-dose radioiodine treatment：results of a double-blind placebo-controlled study［J］. J Clin Oncol，1998，16（11）：3542-3549. DOI：10.1200/JCO.1998.16.11.3542.
［11］BOHUSLAVIZKI K H，KLUTMANN S，BRENNER W，et al. Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment.Results of a double-blinded，placebo-controlled study in patients with differentiated thyroid cancer［J］. Et Al，1999，175（Suppl 4）：6-12.
［12］王聪.131I治疗DTC时维生素C和氨磷汀对唾液腺保护作用研究［D］. 太原：山西医科大学，2016.
［13］李江平.131I治疗DTC患者时维生素C与氨磷汀对唾液腺保护作用的研究［D］. 太原：山西医科大学，2017.
［14］赵波沣，潘明志，谢宗贵，等. 131I治疗分化型甲癌时氨磷汀对唾液腺保护的研究［J］. 中国药物评价，2012，29（2）：123-125.
ZHAO B F，PAN M Z，XIE Z G，et al. Protective effect of amifostine to the salivary gland function of differentiated thyroid cancer after application 131I［J］. Chin J Drug Eval，2012，29（2）：123-125.
［15］肖棋予，罗雯.注射用氨磷汀用于分化型甲状腺癌放射性碘131治疗前对唾液腺的保护作用［J］. 临床合理用药杂志，2020，13（26）：104-106. DOI：10.15887/j.cnki.13-1389/r.2020.26.049.
［16］SON H，LEE S M，YOON R G，et al. Effect of selenium supplementation for protection of salivary glands from iodine-131 radiation damage in patients with differentiated thyroid cancer［J］. Hell J Nucl Med，2017，20（1）：62-70. DOI：10.1967/s002449910508.
［17］BIERMANN M.Selenium supplementation may help protect salivary glands after iodine-131 therapy for differentiated thyroid cancer［J］. Clin Thyroidol，2018，30（1）：21-24. DOI：10.1089/ct.2018;30.21-24.
［18］MAZOKOPAKIS E.Differentiated thyroid cancer and selenium supplements for protection of salivary glands from 131I treatment［J］. Hell J Nucl Med，2018，21（1）：83-84. DOI：10.1967/s002449910712.
［19］NAKADA K，ISHIBASHI T，TAKEI T，et al. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?［J］. J Nucl Med，2005，46（2）：261-266.
［20］王琦，萨日，林秋玉，等. 柠檬酸对分化型甲状腺癌患者首次131I治疗后唾液腺功能的保护作用［J］. 吉林大学学报：医学版，2019，45（4）：911-915. DOI：10.13481/j.1671-587x.20190429.
WANG Q，SA R，LIN Q Y，et al. Protective effect of citric acid on salivary gland function in patients with differentiated thyroid cancer after first 131I treatment［J］. J Jilin Univ：Med Ed，2019，45（4）：911-915. DOI：10.13481/j.1671-587x.20190429.
［21］FALLAHI B，BEIKI D，ABEDI S M，et al. Does vitamin E protect salivary glands from I-131 radiation damage in patients with thyroid cancer?［J］. Nucl Med Commun，2013，34（8）：777-786. DOI：10.1097/MNM.0b013e328362b1f2.
［22］UPADHYAYA A，ZHOU P P，MENG Z W，et al. Radioprotective effect of vitamin E on salivary glands after radioiodine therapy for differentiated thyroid cancer：a randomized-controlled trial［J］. Nucl Med Commun，2017，38（11）：891-903. DOI：10.1097/MNM.0000000000000727.
［23］SAGHARI M，FALLAHI B，BEIKI D，et al. Radioprotective effect of vitamin E against radiation-induced injuries to the salivary glands in radioiodine-treated patients with thyroid cancer［J］. Iranian Journal of Nuclear Medicine，2010，18：21.
［24］王澎，孟召伟，谭建，等. 维生素E对术后首次行131I治疗的分化型甲状腺癌患者唾液腺功能的保护作用［J］. 中华核医学与分子影像杂志，2016，36（5）：398-401. DOI：10.3760/cma.j.issn.2095-2848.2016.05.005.
WANG P，MENG Z W，TAN J，et al. Protective effect of vitamin E to the function of salivary glands in postsurgical patients with differentiated thyroid carcinoma after first 131I ablative therapy［J］. Chinese Journal of Nuclear Medicine and Molecular Imaging，2016，36（5）：398-401. DOI：10.3760/cma.j.issn.2095-2848.2016.05.005.
［25］NAKAYAMA M，OKIZAKI A，TAKAHASHI K.A randomized controlled trial for the effectiveness of aromatherapy in decreasing salivary gland damage following radioactive iodine therapy for differentiated thyroid cancer［J］. Biomed Res Int，2016，2016：9509810. DOI：10.1155/2016/9509810.
［26］NAKAYAMA M，OKIZAKI A.An effectiveness of apitherapy in acute salivary gland disorder following radioactive iodine therapy for differentiated thyroid cancer［J］. The Journal of Nuclear Medicine，2019，60（S1）.
［27］SON S H，LEE C H，JUNG J H，et al. The preventive effect of parotid gland massage on salivary gland dysfunction during high-dose radioactive iodine therapy for differentiated thyroid cancer：a randomized clinical trial［J］. Clin Nucl Med，2019，44（8）：625-633. DOI：10.1097/rlu.0000000000002602.
［28］KIM S J，CHOI H Y，KIM I J，et al. Limited cytoprotective effects of amifostine in high-dose radioactive iodine 131-treated well-differentiated thyroid cancer patients：analysis of quantitative salivary scan［J］. Thyroid，2008，18（3）：325-331. DOI：10.1089/thy.2007.0191.
［29］MA C，XIE J W，CHEN Q F，et al. Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer［J］. Cochrane Database Syst Rev，2009（4）：CD007956. DOI：10.1002/14651858.CD007956.pub2.
［30］MA C，XIE J W，JIANG Z X，et al. Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer［J］. Eur J Nucl Med Mol Imaging，2010，37（9）：1778-1785. DOI：10.1007/s00259-009-1368-6.
［31］JENTZEN W，RICHTER M，NAGARAJAH J，et al. Chewing-gum stimulation did not reduce the absorbed dose to salivary glands during radioiodine treatment of thyroid cancer as inferred from pre-therapy（124）I PET/CT imaging［J］. EJNMMI Phys，2014，1（1）：100. DOI：10.1186/s40658-014-0100-1.
［32］SILBERSTEIN E B.Reducing the incidence of 131I-induced sialadenitis：the role of pilocarpine［J］. J Nucl Med，2008，49（4）：546-549. DOI：10.2967/jnumed.107.049411.
［33］HIGGINS J P，GREEN S.Cochrane handbook for systematic reviews of interventions［M］. United Kingdom：John Wiley ＆ Sons Ltd，2019.
［34］曾宪涛，庄丽萍，杨宗国，等. Meta分析系列之七：非随机实验性研究、诊断性试验及动物实验的质量评价工具［J］. 中国循证心血管医学杂志，2012，4（6）：496-499.
［35］SHIM S，YOON B H，SHIN I S，et al. Network meta-analysis：application and practice using Stata［J］. Epidemiol Health，2017，39：e2017047. DOI：10.4178/epih.e2017047.
［36］HANSEN C H，WARNER P，WALKER A，et al. A practical guide to pre-trial simulations for Bayesian adaptive trials using SAS and BUGS［J］. Pharm Stat，2018，17（6）：854-865. DOI：10.1002/pst.1897.
［37］CHEN L Y，LIANG X Y，JIANG J S，et al. Carbapenems vs tigecycline for the treatment of complicated intra-abdominal infections：a Bayesian network meta-analysis of randomized clinical trials［J］. Medicine（Baltimore），2019，98（40）：e17436. DOI：10.1097/MD.0000000000017436.
［38］姚岚，黄启成.老年分化型甲状腺癌患者术后首次行131I治疗中维生素E对唾液腺功能的影响［J］. 中国老年学杂志，2017，37（15）：3784-3786.
［39］李玉娟，祁岗，李海燕.131碘联合丙硫氧嘧啶对老年甲状腺癌患者术后唾液腺及甲状腺功能的影响［J］. 中国老年学杂志，2020，40（21）：4537-4539.
［40］PROCTOR G B.The physiology of salivary secretion［J］. Periodontol，2016，70（1）：11-25. DOI：10.1111/prd.12116.
［41］MANDEL S J，MANDEL L.Radioactive iodine and the salivary glands［J］. Thyroid，2003，13（3）：265-271. DOI：10.1089/105072503321582060.
［42］MALPANI B L，SAMUEL A M，RAY S.Quantification of salivary gland function in thyroid cancer patients treated with radioiodine［J］. Int J Radiat Oncol，1996，35（3）：535-540. DOI：10.1016/S0360-3016（96）80016-2.
［43］MANDEL S J，MANDEL L.Radioactive iodine and the salivary glands［J］. Thyroid，2003，13（3）：265-271. DOI：10.1089/105072503321582060.
［44］CHRISTOU A，PAPASTAVROU E，MERKOURIS A，et al. Clinical studies of nonpharmacological methods to minimize salivary gland damage after radioiodine therapy of differentiated thyroid carcinoma：systematic review［J］. Evid Based Complement Alternat Med，2016，2016：6795076. DOI：10.1155/2016/6795076.
［45］JEONG S Y，KIM H W，LEE S W，et al. Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer：direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms［J］. Thyroid，2013，23（5）：609-616. DOI：10.1089/thy.2012.0106.
［46］LIU B，KUANG A R，HUANG R，et al. Influence of vitamin C on salivary absorbed dose of 131I in thyroid cancer patients：a prospective，randomized，single-blind，controlled trial［J］. J Nucl Med，2010，51（4）：618-623. DOI：10.2967/jnumed.109.071449.
［47］RAMOS F M，PONTUAL M L，DE ALMEIDA S M，et al. Evaluation of radioprotective effect of vitamin E in salivary dysfunction in irradiated rats［J］. Arch Oral Biol，2006，51（2）：96-101. DOI：10.1016/j.archoralbio.2005.06.008.
［48］WEISS J F，LANDAUER M R.Protection against ionizing radiation by antioxidant nutrients and phytochemicals［J］. Toxicology，2003，189（1/2）：1-20. DOI：10.1016/s0300-483x（03）00149-5.
［49］BHARTIYA U S，RAUT Y S，JOSEPH L J，et al. Evaluation of the radioprotective effect of turmeric extract and vitamin E in mice exposed to therapeutic dose of radioiodine［J］. Indian J Clin Biochem，2008，23（4）：382-386. DOI：10.1007/s12291-008-0084-5.

[1]	QUAN Jialin, ZHU Lin, SU Yu, CHEN Zekai, CHEN Ziqi, ZHANG Zhuofan. Research on the Improvement Effect of Exercise Modes on the Executive Function of Overweight or Obese Children or Adolescents: a Network Meta-analysis [J]. Chinese General Practice, 2025, 28(27): 3422-3431.
[2]	LI Hao, LI Jiangtao, LIU Dan, WANG Jianjun. Efficacy and Safety of Belimumab, Anifrolumab, and Telitacicept on the Treatment of Systemic Lupus Erythematosus: a Network Meta-analysis [J]. Chinese General Practice, 2025, 28(23): 2924-2933.
[3]	ZHU Shengjie, DIAO Huaqiong, HANG Xiaoyi, SUN Wenjun. Network Meta-analysis of Different Traditional Chinese Medicine Injections for the Treatment of Posterior Circulatory Ischemic Vertigo [J]. Chinese General Practice, 2025, 28(14): 1795-1808.
[4]	CHI Xun, LIU Sisi, CHEN Qiao, HU Yue, WANG Weixian. The Suitability of Four Nutritional Screening Tools for Nutritional Screening in Patients with Cirrhosis: a Network Meta-analysis [J]. Chinese General Practice, 2025, 28(11): 1395-1402.
[5]	GU Mingyu, QIN Tingting, QIAO Kun, BAI Xinyuan, WANG Yao, YANG Yutong, LI Xingming. A Network Meta-analysis of Primary Hypertension Management Patterns in China [J]. Chinese General Practice, 2025, 28(10): 1265-1272.
[6]	GUO Jia, CAO Chunmei, LIU Guochun, ZHENG Man, ZHU Ruihan, LONG Wei. Effects of Different Exercise Types on Sleep in Insomnia Patients: a Network Meta-analysis [J]. Chinese General Practice, 2024, 27(35): 4376-4387.
[7]	HUANG Tengjia, CAO Xi, CHEN Lei, LI Ziying, QIN Lihua. The Effectiveness of Non-pharmacological Treatment for Post-stroke Shoulder-hand Syndrome: a Network Meta-analysis [J]. Chinese General Practice, 2024, 27(23): 2921-2930.
[8]	WANG Ting, WANG Haiyan, FU Wenjun. Effect of Chronic Atrophic Gastritis Treated with Different Acupuncture and Moxibustion Therapies: a Network Meta-analysis [J]. Chinese General Practice, 2024, 27(23): 2913-2920.
[9]	TAN Shufa, ZHANG Leichang, GAO Qiangqiang, OU Yan, HUANG Shuilan. Efficacy and Safety of Biologics and Small Molecule Drugs in the Treatment of Ulcerative Colitis: a Network Meta-analysis [J]. Chinese General Practice, 2024, 27(17): 2155-2166.
[10]	BAI Xin, WU Xinyu, ZHAO Zun, LIU Shuxin, LIU Simiao, XUE Yuhang, XU Junling, GAO Yongju. Efficacy Analysis of ¹³¹I Therapy in Serum Thyroglobulin Antibody Positive Differentiated Thyroid Carcinoma with Distant Metastasis [J]. Chinese General Practice, 2024, 27(15): 1833-1837.
[11]	NIU Jingyuan, CHEN Huisheng, YU Jiaxiang, CUI Yu. Ligustrazine Injection in the Treatment of Acute Ischemic Stroke: a Bayesian Network Meta-analysis [J]. Chinese General Practice, 2024, 27(14): 1761-1774.
[12]	HE Jingyi, WANG Fang, SHUI Xiaoling, LI Ling, LIANG Qian. Efficacy of Non-pharmacological Interventions to Improve Perimenopausal Insomnia Symptoms: a Network Meta-analysis [J]. Chinese General Practice, 2023, 26(31): 3963-3974.
[13]	ZHU Lin, GUO Yankui, GAO Chen, CHEN Xuezhi, WANG Fashuai. Efficacy of Western Medicine, Chinese Patent Medicine and Their Combination on Post-stroke Insomnia: a Network Meta-analysis [J]. Chinese General Practice, 2023, 26(30): 3823-3832.
[14]	WANG Xueyan, TIAN Jinhui, ZHANG Li, ZHAI Jinguo. Effects of Different Intervention Measures for Breech Presentation/Transverse Lie Position on Maternal and Neonatal Outcomes: a Network Meta-analysis [J]. Chinese General Practice, 2023, 26(21): 2647-2658.
[15]	LI Lingling, HUANG Hailiang, YU Ying, JIA Yuqi, LIU Zhiyao, SHI Xin, WANG Fangqi, LIU Xinyue. Effect of Non-invasive Brain Stimulation on Autism Spectrum Disorder: a Systematic Review and Network Meta-analysis [J]. Chinese General Practice, 2023, 26(11): 1389-1397.